home / stock / tcon / tcon news

TCON News and Press, TRACON Pharmaceuticals Inc. From 08/30/22

Stock Information
Company Name: TRACON Pharmaceuticals Inc.
Stock Symbol: TCON
Market: OTC
Website: traconpharma.com
Menu
TCON TCON Quote TCON Short TCON News TCON Articles TCON Message Board
Get TCON Alerts

News, Short Squeeze, Breakout and More Instantly...
TCON - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com It’s time for another breakdown of the biggest pre-market stock movers as we go over the latest news on Tuesday morning. Moving stocks this morning is a turnaround plan,...
TCON - TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q2 2022 Results - Earnings Call Transcript

TRACON Pharmaceuticals, Inc. (TCON) Q2 2022 Earnings Conference Call August 10, 2022, 04:30 PM ET Company Participants Charles Theuer - President and Chief Executive Officer Scott Brown - Chief Financial Officer Conference Call Participants Maury Raycroft...

TCON - Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M

Tracon press release ( NASDAQ: TCON ): Q2 GAAP EPS of -$0.31 beats by $0.05 . Revenue of $0M. For further details see: Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M

TCON - TRACON Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with oth...
TCON - TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with oth...

TCON - TRACON to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 10, 2022

SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other lif...

TCON - TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with oth...
TCON - Anebulo, Tenon top healthcare gainers; BioSig, Rigel lead losers' pack

Gainers: Anebulo Pharmaceuticals (ANEB) +32%. Tenon Medical (TNON) +19%. PolarityTE (PTE) +14%. TRACON Pharmaceuticals (TCON) +14%. Bausch Health (BHC) +13%. Losers: BioSig Technologies (BSGM) -26%. Rigel Pharmaceuticals (RIGL) -8%. Valneva (VALN) ...

TCON - TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform ...

TCON - TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...
Previous 10 Next 10